Enfusion (NYSE:ENFN) Shares Gap Up – Should You Buy?

Shares of Enfusion, Inc. (NYSE:ENFN) gapped up prior to trading on Monday . The stock had previously closed at $9.94, but opened at $10.80. Enfusion shares last traded at $10.84, with a volume of 702,654 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ENFN shares. Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus upped their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.25.

Enfusion Trading Up 8.1 %

The firm has a fifty day moving average price of $10.11 and a 200 day moving average price of $9.20. The firm has a market cap of $1.38 billion, a PE ratio of 268.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95.

Insiders Place Their Bets

In other news, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,404 shares of company stock valued at $580,130 over the last ninety days. Company insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Centiva Capital LP lifted its holdings in Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after buying an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares in the last quarter. Azora Capital LP boosted its holdings in Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after purchasing an additional 1,890 shares during the period. 272 Capital LP grew its stake in Enfusion by 1.5% during the 2nd quarter. 272 Capital LP now owns 139,180 shares of the company’s stock worth $1,186,000 after purchasing an additional 2,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after purchasing an additional 4,239 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.